The story has been updated to include comments from Danaher's conference call this morning.

NEW YORK (GenomeWeb News) – Danaher's sales for the third quarter rose 6 percent year over year as its Life Sciences and Diagnostics segment grew almost 11 percent, the company reported today.

For the three months ended Sept. 27, the Washington-based conglomerate saw sales improve to $4.67 billion from $4.42 billion a year ago, edging out the consensus Wall Street estimate of $4.62 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.